Arbutus Biopharma Corporation

Contributing Author

Recent Articles by Arbutus Biopharma Corporation

Jun-25	Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus ABUS GlobeNewswire
May-14	Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update ABUS GlobeNewswire
May-07	Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 ABUS GlobeNewswire